Skip to content

Luxembourg French logo

Main menu
    • À propos
    • Notre vision, raison d’être, et mission
    • Nos valeurs
    • Nos engagements RSE
  • Nos domaines d’intervention
  • Espace Presse
  • Professionnels de Santé
  • Nous rejoindre

Nous Contacter

Back
Change Language
  • English (Luxembourg)
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Lancement d’Organon Heist

Save Print

June 10, 2021 4:00 pm EDT

HEIST-OP-DEN-BERG – Le lancement de l’établissement producteur d’Organon à Heist-op-den-Berg le 9 juin était l’occasion parfaite de montrer l’engagement d’Organon pour l’amélioration de la santé féminine. Le site existe depuis près de 50 ans et fait désormais partie d’Organon depuis le lancement de la nouvelle société le 3 juin.

François Marivoet (directeur d’usine Organon Heist) et Petra Willems (directrice générale d’Organon Benelux) ont présenté la société aux parties prenantes et aux médias. Les personnes invitées à la séance d’ouverture étaient Claire Tillekaerts (PDG de Flanders Invest & Trade, à droite sur la photo) et Luc Vleugels, maire de Heist-op-den-Berg (à gauche).

Au Benelux, Organon emploie environ vingt pour cent de son personnel et compte deux établissements producteurs sur six. Les infrastructures modernes d’Organon implantées à Heist-op-den-Berg, en Belgique, produisent chaque année 160 millions d’unités pour une patientèle répartie sur plus de 140 pays. Sur les 2 000 personnes employées par la société au Benelux, environ 900 travaillent à Heist.

Organon concentre son activité sur la santé féminine. Le site de Heist est spécialisé dans la production et le conditionnement modernes de comprimés, de produits stériles, de liquides, d’onguents et de crèmes (marques établies), ainsi que dans le conditionnement de produits biotechnologiques issus d’autres sites.

VVPM job number Launch of Organon Heist news article: BE-NON-110069

What can we help you find?

Search for:
Luxembourg French logo
  • Politique de gestion de cookies
  • Politique de confidentialité
  • Conditions générales d’utilisation
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept